Patents by Inventor Florian Von Der Mulbe
Florian Von Der Mulbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181765Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.Type: ApplicationFiled: January 13, 2016Publication date: June 15, 2023Applicant: CureVac SEInventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
-
Patent number: 11661634Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: July 21, 2022Date of Patent: May 30, 2023Assignee: CureVac Manufacturing GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Publication number: 20230157958Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: August 26, 2022Publication date: May 25, 2023Applicant: CureVac Manufacturing GmbHInventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Publication number: 20230053382Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: July 21, 2022Publication date: February 23, 2023Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Patent number: 11491112Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: December 5, 2021Date of Patent: November 8, 2022Assignee: CureVac Manufacturing GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Patent number: 11458100Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: December 5, 2021Date of Patent: October 4, 2022Assignee: CureVac Manufacturing GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Patent number: 11446250Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: August 17, 2020Date of Patent: September 20, 2022Assignee: CureVac Real Estate GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Patent number: 11369691Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.Type: GrantFiled: January 25, 2016Date of Patent: June 28, 2022Assignee: CureVac AGInventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
-
Publication number: 20220160638Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: December 5, 2021Publication date: May 26, 2022Applicant: CureVac Real Estate GmbHInventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Publication number: 20220154253Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Patent number: 11268157Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: June 2, 2020Date of Patent: March 8, 2022Assignee: CureVac Real Estate GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Patent number: 11135312Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.Type: GrantFiled: September 16, 2014Date of Patent: October 5, 2021Assignee: CureVac AGInventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
-
Publication number: 20200383922Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: August 17, 2020Publication date: December 10, 2020Applicant: CureVac Real Estate GmbHInventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Publication number: 20200308634Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: June 2, 2020Publication date: October 1, 2020Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Patent number: 10780054Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: April 15, 2016Date of Patent: September 22, 2020Assignee: CureVac Real Estate GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Patent number: 10711315Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: June 11, 2018Date of Patent: July 14, 2020Assignee: CureVac Real Estate GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Patent number: 10568972Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.Type: GrantFiled: January 25, 2016Date of Patent: February 25, 2020Assignee: CureVac AGInventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
-
Publication number: 20190134222Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.Type: ApplicationFiled: August 29, 2018Publication date: May 9, 2019Applicant: CureVac AGInventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
-
Patent number: 10188748Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilized by sequence modifications and optimized for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilization and translational efficiency of modified mRNA of the invention.Type: GrantFiled: December 5, 2003Date of Patent: January 29, 2019Assignee: CureVac AGInventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
-
Publication number: 20180282790Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: June 11, 2018Publication date: October 4, 2018Applicant: CureVac AGInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID